Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial
Open Access
- 25 October 2025
- journal article
- Published by Elsevier in Obesity Pillars
- Vol. 16, 100220
Abstract
No abstract availableKeywords
Funding Information
- Eli Lilly and Company
This publication has 34 references indexed in Scilit:
- LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trialThe Lancet, 2022
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of conceptCell Metabolism, 2022
- A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage onMetabolism, 2022
- An update on obesity: Mental consequences and psychological interventionsDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2019
- Informing a priori Sample Size Estimation in Qualitative Concept Elicitation Interview Studies for Clinical Outcome Assessment Instrument DevelopmentValue in Health, 2018
- The Psychosocial Burden of ObesityEndocrinology and Metabolism Clinics of North America, 2016
- Dress fit and body image: A thematic analysis of women's accounts during and after trying on dressesBody Image, 2013
- The impact of obesity on quality of lifeBest Practice & Research Clinical Endocrinology & Metabolism, 2013
- Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studiesThe Lancet, 2009
- Association Between Obesity and Psychiatric Disorders in the US Adult PopulationArchives of General Psychiatry, 2006